Get the Stockscreener App
34.94
17.05%
5.09
After Hours:
36.52
1.58
+4.52%
Cue Biopharma Inc stock is traded at $34.94, with a volume of 622.75K.
It is up +17.05% in the last 24 hours and up +547.40% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$29.85
Open:
$30.23
24h Volume:
622.75K
Relative Volume:
0.97
Market Cap:
$113.74M
Revenue:
$27.47M
Net Income/Loss:
$-26.60M
P/E Ratio:
-7.57
EPS:
-4.6156
Net Cash Flow:
$-21.86M
1W Performance:
+180.53%
1M Performance:
+547.40%
6M Performance:
+58.83%
1Y Performance:
+49.66%
1-Day Range:
$29.50
$35.50
1-Week Range:
$12.00
$38.00
52-Week Range:
$4.971
$38.00
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
34.94 | 97.17M | 27.47M | -26.60M | -21.86M | -4.6156 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Cue Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Cue Biopharma (CUE) Stock Surges Following Financing Deal and Le - GuruFocus
Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise - TechStock²
Cue Biopharma jumps as investors react to Ascendant-221 licensing deal and fresh financing news - Quiver Quantitative
Cue Biopharma licenses Ascendant-221 and raises new capital - TipRanks
Cue Biopharma Raises $30 Million in Private Placement to Advance Immunology Pipeline - citybiz
MSN Money - MSN
Cue resets strategy with new CEO, pipeline deal and $30m financing - The Pharma Letter
Cue Biopharma raises $30M in private placement - MSN
Cue Biopharma appoints Shao-Lee Lin as CEO and president - Investing.com UK
CUE Stock Quote Price and Forecast - CNN
CUE Stock Price, Quote & Chart | CUE BIOPHARMA INC (NASDAQ:CUE) - ChartMill
Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving? - Benzinga
$Cue Biopharma (CUE.US)$ - Moomoo
Cue Biopharma secures $30M private placement financing - Investing.com UK
Cue Biopharma Secures $30 Million Financing and New CEO - Intellectia AI
Cue Biopharma (CUE) Secures $30M in Private Placement Financing - GuruFocus
Cue Biopharma Names Lin as CEO, Secures Exclusive License Agreement With Ascendant Health Sciences - Moomoo
Cue Biopharma unveils leadership changes, pipeline milestones and financing to drive phase 2 strategy - Traders Union
Cue Biopharma secures $30M private placement financing By Investing.com - Investing.com Australia
Cue Biopharma Announces $30 Million Private P - Moomoo
Cue Biopharma licenses anti-IgE antibody for allergic diseases By Investing.com - Investing.com South Africa
Cue Biopharma appoints Shao-Lee Lin as CEO and president By Investing.com - Investing.com Australia
Cue Biopharma lines up $30M to fund pipeline and Ascendant-221 - Stock Titan
Cue Biopharma licenses anti-IgE antibody for allergic diseases - Investing.com
Cue pays $15M for allergy drug, targets food allergy trial - Stock Titan
Cue Biopharma Announces $30 Million PIPE Financing Agreement to Advance Clinical Pipeline - Quiver Quantitative
Press Release: Cue Biopharma Announces $30 Million Private Placement - Moomoo
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody - The Manila Times
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company - The Manila Times
CUE - Finviz
Cue Biopharma, Inc. Revenue Breakdown – SWB:1UC0 - TradingView
Current ratio of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Taxes of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — SWB:1UC0 - TradingView
Cue Biopharma (CUE) price target increased by 2,900.00% to 122.40 - MSN
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma (FRA:1UC0) Unearned Income - GuruFocus
Cue Biopharma, Inc. Income Statement – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Cash Flow – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — GETTEX:1UC0 - TradingView
Equity in earnings of Cue Biopharma, Inc. – LSX:A426PN - TradingView
Cue Biopharma, Inc. Cash Flow – LSX:A426PN - TradingView
Equity in earnings of Cue Biopharma, Inc. – GETTEX:1UC0 - TradingView
Net debt of Cue Biopharma, Inc. – GETTEX:1UC0 - TradingView
Cue Biopharma, Inc. Trade Ideas — LSX:A426PN - TradingView
Cue Biopharma, Inc. Balance Sheet – LSX:A426PN - TradingView
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):